# Human TNFRSF17 / BCMA (CD269) Protein (His Tag)

Catalog Number: 10620-H08H



# **General Information**

#### Gene Name Synonym:

BCM; BCMA; CD269; TNFRSF13A

#### **Protein Construction:**

A DNA sequence encoding the human TNFRSF17 (NP\_001183.2) (Met1-Ala54) was expressed with a polyhistidine tag at the C-terminus.

Source: Human

Expression Host: HEK293 Cells

**QC** Testing

**Purity:** > 95 % as determined by SDS-PAGE.

**Endotoxin:** 

< 1.0 EU per  $\mu g$  protein as determined by the LAL method.

Stability:

Samples are stable for up to twelve months from date of receipt at -70  $^{\circ}$ C

Predicted N terminal: Met 1

**Molecular Mass:** 

The recombinant human TNFRSF17 consists of 65 amino acids and predicts a molecular mass of 7.3 kDa.

## Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

# **Usage Guide**

## Storage:


Store it under sterile conditions at  $-20\,^{\circ}\mathrm{C}$  to  $-80\,^{\circ}\mathrm{C}$  upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

## Reconstitution:

Detailed reconstitution instructions are sent along with the products.

#### SDS-PAGE:



# **Protein Description**

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

#### References

1.Novak AJ, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689–94. 2.O'Connor BP, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199(1): 91-8. 3.Moser K, et al. (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

For US Customer: Fax: 267-657-0217 • Tel: 215-583-7898

Global Customer: Fax :+86-10-5862-8288 
■ Tel:+86-400-890-9989 
■ http://www.sinobiological.com